Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2026-05-13 am EDT			5-day change	1st Jan Change
299.20 ^DKK	+0.91%		+2.12%	-8.01%

09:15am	Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Wednesday Ahead of US-China Meeting	MT
08:11am	Novo Nordisk Canada and Rexall Pharmacy partner to offer convenience, support, and home delivery for Canadians taking Ozempic and Wegovy	RE

BNP Paribas cuts Novo Nordisk price target to DKK 295 (302), reiterates Neutral - BN

Published on 04/17/2026 at 12:43 am EDT

Finwire - Translated by Marketscreener - See original

NOVO NORDISK A/S

+0.91%

BNP Paribas has lowered its price target for Novo Nordisk to DKK 295 from DKK 302, while maintaining its Neutral rating - BN

Latest news about Novo Nordisk A/S

09:15am	Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Wednesday Ahead of US-China Meeting	MT
08:11am	Novo Nordisk Canada and Rexall Pharmacy partner to offer convenience, support, and home delivery for Canadians taking Ozempic and Wegovy	RE
06:57am	Novo Nordisk Says Wegovy Pill Delivered Substantial Weight Loss, Mobility Improvement in Phase 3 Trial Analyses	MT
06:52am	Novo Nordisk Pauses Manufacturing Plans at Odense Site, Layoff 150 Workers	MT
06:41am	Denmark's Novo Nordisk Halts Development of Manufacturing Facility in Odense	MT
05:44am	Novo Nordisk halts Odense construction and issues layoff notices	FW
03:17am	Novo Nordisk Says Trial of Wegovy Pill Shows Some Patients Achieve Nearly 22% Weight Loss	DJ
03:16am	Novo Nordisk says Wegovy pill delivers 21.6% weight loss in early responders	RE
02:47am	NOVO NORDISK : Jefferies reaffirms its Neutral rating	ZD
02:27am	Novo Nordisk: Oral Wegovy yields over 21 percent weight loss in clinical trial	FW
01:48am	GLP-1: Winners and Losers in Shifting Consumer Habits
06:05pm	Patients don't regain much weight switching from injections to Lilly's weight-loss pill, study finds	RE
May. 12	Novo Nordisk A/S Demonstrates Higher Dose Wegovy Achieves Nearly 28% Weight Loss in Early Responders	CI
May. 12	Dr. Reddy's to Launch Generic Ozempic in Canada This Month	MT
May. 12	Dr. Reddy's to Launch Generic Ozempic in Canada This Month, Bloomberg Reports	MT

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.7%); - rare disease treatment products (6.3%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe and Canada (21.4%), the United States (56%), Latin America/Middle East/Africa (9.9%), China/Hong Kong/Taiwan (6%), Asia/Pacific (6.7%).

Employees

67,900

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company